Durability of SVR in chronic hepatitis C patients treated with peginterferon‐α2a/ribavirin in combination with a direct‐acting anti‐viral. Issue 2 (26th May 2013)

• Record Type: Journal Article
• Authors: Rutter, K.; Hofer, H.; Beinhardt, S.; Dulic, M.; Gschwantler, M.; Maieron, A.; Laferl, H.; Stättermayer, A. F.; Scherzer, T.‐M.; Strassl, R.; Holzmann, H.; Steindl‐Munda, P.; Ferenci, P.
• Is Part Of: Alimentary pharmacology & therapeutics. Volume 38:Issue 2(2013)
• Page Start: 118
• Page End: 123
• Publication Date: 2013-05-26
• Subjects: Digestive organs -- Diseases -- Treatment -- Periodicals; Digestive organs -- Effect of drugs on -- Periodicals; Gastrointestinal system -- Diseases -- Treatment -- Periodicals; Gastrointestinal system -- Effect of drugs on -- Periodicals; 615.73
• DOI: 10.1111/apt.12350
• Languages: English
• ISSNs: 0269-2813

Abstract

<abstract abstract-type="main" id="apt12350-abs-0001"> <title>Summary</title> <sec id="apt12350-sec-0001" sec-type="section"> <title>Background</title> <p>The introduction of direct‐acting anti‐virals has increased sustained virological response (SVR) rates in chronic hepatitis C genotype 1 infection. At present, data on long‐term durability of viral eradication after successful triple therapy are lacking.</p> </sec> <sec id="apt12350-sec-0002" sec-type="section"> <title>Aim</title> <p>To evaluate the long‐term durability of viral eradication in patients treated with triple therapy, including direct‐acting anti‐virals.</p> </sec> <sec id="apt12350-sec-0003" sec-type="section"> <title>Methods</title> <p>Patients who participated in randomised, controlled trials or an extended access programme of treatment with peginterferon‐α2a/ribavirin in combination with a direct‐acting anti‐viral (telaprevir, danoprevir, faldaprevir, simeprevir, mericitabine, balapiravir) were followed after achieving SVR. The median follow‐up after the patients was 21 (range: 7–64) months.</p> </sec> <sec id="apt12350-sec-0004" sec-type="section"> <title>Results</title> <p>One hundred and three patients with chronic hepatitis C genotype 1 infection [f/m: 34/69; GT‐1b: 67 GT‐1a: 34, GT‐4: 2; mean age: 47.6 years (45.5–49.7; 95% CI)] achieving a SVR triple therapy were followed. Two cases of late relapses (2/103, 1.9%; 95% CI: 0.24–6.8) were observed. One patient was cirrhotic, both carried the genotype 1b and completed the prescribed treatment. The relapses occurred 8 and 12 months after cessation of anti‐viral treatment. Cloning sequencing revealed identical sequence in both patients. Resistance analysis revealed no presence of viral resistance.</p> </sec> <sec id="apt12350-sec-0005" sec-type="section"> <title>Conclusion</title> <p>Like the SVR after peginterferon‐α2/ribavirin combination treatment, HCV eradication after triple therapy remains durable after long‐term follow‐up.</p> </sec> </abstract>